With the patent for Clobex (clobetasol propionate) facing an expiration of September 22, 2017, this prescription medication used to treat adults and children 12 years and older with psoriasis is sure to have generic development. Clobetasol propionate is available as a topical steroid spray, and it is effectual as it decreases inflammation and suppresses an[…]
Clobetasol Continues to Prove Its Efficacy in Psoriasis
Anti-Inflammatory, Anti-Psoriatic, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2017 Tags: plaque psoriasisPsoriasis Jan 28, 2013
Patients with Plaque Psoriasis Find Relief with Betamethasone Valerate
Anti-Inflammatory, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2016 Tags: plaque psoriasis Sep 24, 2012
The National Psoriasis Foundation reports that 7.5 million Americans suffer from psoriasis. This staggering number only highlights the need for effective and safe medications to treat this frustrating, embarrassing and uncomfortable condition. Betamethasone Valerate is known as Luxiq, which is marketed by Stiefel and GlaxoSmithKline. As an aerosol foam treatment for patients with scalp psoriasis,[…]
Vitamin D Analogues Clinically Useful for Several Conditions
Anti-Psoriatic, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Hypocalcemia, Osteoporosis Tags: hypocalcemiaosteoporosisplaque psoriasisPsoriasisvitamin D May 02, 2012
Calcium regulation in the human body. The role of vitamin D is shown in orange. There are several active pharmaceutical ingredient products known as vitamin D analogues, which are derivatives of this powerful vitamin, designed to aid patients’ health and well being. Vitamin D is known by many people as the vitamin that helps to[…]
Infrequent Dosing of Ustekinumab is Appealing to Patients with Plaque Psoriasis
Drug Research & Development API, Monoclonal Antibodies / mAb Tags: Etanerceptplaque psoriasis Mar 14, 2012
Ustekinumab, CAS number 815610-63-0, is also known by it’s brand name Stelara, which is marketed by Janssen Biotech, Inc. Developed as a treatment for adults with moderate to severe plaque psoriasis, which may involve vast areas of their body, Stelara is unique in it’s dosing. Stelara, or ustekinumab, is typically given twice in the first[…]
Etanercept Offers Relief for Patients with Rheumatoid Arthritis
Anti-Inflammatory, Anti-Psoriatic, Drug Research & Development API Tags: Etanerceptplaque psoriasisRheumatoid Arthritis Mar 13, 2012
Etanercept, known by the trade name Enbrel, is indicated for reducing the signs and symptoms of Rheumatoid Arthritis. In addition, etanercept, CAS number 185243-69-0, is effective in reduction of symptoms as related to Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Plaque Psoriasis. Developed by researchers at Immunex, etanercept is marketed as Enbrel by[…]
